Washington Trust Advisors’s Bio-Techne TECH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$665 Sell
9
-18
-67% -$972 ﹤0.01% 712
2026
Q1
$1.42K Sell
27
-94
-78% -$5.64K ﹤0.01% 606
2025
Q4
$7.12K Buy
121
+108
+831% +$6.56K ﹤0.01% 529
2025
Q3
$723 Buy
+13
New +$696 ﹤0.01% 682
2025
Q2
– Sell
-36
Closed -$2.11K – 651
2025
Q1
$2.11K Sell
36
-30
-45% -$2.03K ﹤0.01% 610
2024
Q4
$4.78K Buy
66
+6
+10% +$441 ﹤0.01% 578
2024
Q3
$4.83K Buy
60
+10
+20% +$751 ﹤0.01% 578
2024
Q2
$3.58K Hold
50
– – ﹤0.01% 595
2024
Q1
$3.52K Hold
50
– – ﹤0.01% 610
2023
Q4
$3.86K Hold
50
– – ﹤0.01% 598
2023
Q3
$3.4K Hold
50
– – ﹤0.01% 594
2023
Q2
$4.08K Hold
50
– – ﹤0.01% 570
2023
Q1
$3.71K Sell
50
-282
-85% -$21.7K ﹤0.01% 657
2022
Q4
$27.5K Sell
332
-1,224
-79% -$97.2K ﹤0.01% 379
2022
Q3
$110K Sell
1,556
-172
-10% -$14.9K 0.01% 267
2022
Q2
$150K Buy
1,728
+48
+3% +$4.5K 0.01% 234
2022
Q1
$182K Sell
1,680
-92
-5% -$9.49K 0.01% 253
2021
Q4
$229K Buy
+1,772
New +$217K 0.02% 233

Other funds holding TECH

Washington Trust Advisors's TECH Position: Q2 2026 in Review

Washington Trust Advisors reduced its Bio-Techne (TECH) stake by 67% in Q2 2026, selling an estimated $972 and leaving 9 shares worth $665. The position accounts for ﹤0.01% of the portfolio, ranked #712.

Washington Trust Advisors first reported a position in TECH in Q4 2021 and has held it in 18 quarters since. The position peaked at $229K in Q4 2021. 597 funds tracked by Wall St. Rank hold TECH as of Q2 2026.

  • Washington Trust Advisors held 9 shares of Bio-Techne worth $665 as of Q2 2026.
  • Washington Trust Advisors sold 18 Bio-Techne shares in Q2 2026, an estimated $972.
  • Bio-Techne made up ﹤0.01% of Washington Trust Advisors's portfolio in Q2 2026, its #712 holding.
  • Washington Trust Advisors first reported a position in Bio-Techne in Q4 2021 and has held it in 18 quarters since.
  • Washington Trust Advisors's Bio-Techne position peaked at $229K in Q4 2021.
  • 597 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2026.

Based on Washington Trust Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.